Tardive dyskinesia: Epidemiology

• Published in: Journal of the neurological sciences 2018-06, Vol.389, p.17-20
• Main Authors: D'Abreu, Anelyssa, Akbar, Umer, Friedman, Joseph H.
• Format: Article
• Language: English
• ISSN: 0022-510X; 1878-5883
• DOI: 10.1016/j.jns.2018.02.007

The term tardive syndrome (TS) encompasses a few different phenomenologic conditions, some of which occur in isolation and others in association with each other. This, along with the unusual confound for a drug side effect, in which increased use of the drug improves the problem, and the need for most patients to continue taking the offending drug, makes understanding the epidemiology difficult and unreliable. While the change from the “first generation” to the “second generation” of antipsychotic drugs is generally believed to have reduced the incidence of TS, prospective research studies have not supported that contention. Published reports have found point prevalences of 13% with second generation antipsychotics and 32% with first, yet others have found no differences. One study found increasing rates of TS with a 68% prevalence by 25 years, while another found a decreased prevalence over time, due presumably to masking effects of the antipsychotic drugs. Regardless of the possible differences, it is clear that TS remains a significant and common problem associated with almost all antipsychotic drugs. There have also been scattered reports of TS caused by drugs not known to inhibit dopamine receptors. These are reviewed and were found to be often of dubious reliability.